Trial Profile

A Phase I Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin Plus Escalating Doses of Inotuzumab Ozogamicin (DA-EPOCH-InO) in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Inotuzumab ozogamicin (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Prednisone; Vincristine
Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions

03 Jul 2023 Status changed from active, no longer recruiting to completed.
06 Jun 2023 Results assessing the maximum tolerated dose (MTD) of InO when added to DA-EPOCH presented at the 59th Annual Meeting of the American Society of Clinical Oncology
02 Jun 2023 According to Adaptive Biotechnologies Media Release, data from this study will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Hybrid Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com